Stocks to watch, Sept 4: BSE, UltraTech Cement, Polycab, KEI Industries, Cipla, Ceigall India, IEX, Bharat Forge

The domestic stock market is expected to open in the green on Friday, September 4. The GIFT NIFTY futures suggest that the NIFTY50 index will open 56 points higher.

In a statement on Thursday, SEBI said it may propose changes to the existing methodology, with a consultation paper on the proposed framework likely to be released in about a week.

The group aims to become one of the top two players in the wires and cables segment within five years and is entering the market with the second-largest capacity for wire production.

The acceptance period for the offer, at a consideration of €14.10 per Iveco share, will run from September 7 to October 26, 2026, unless extended.

The product, QL2107, is a biosimilar to pembrolizumab (Keytruda) and aims to improve access to advanced therapies for cancer patients while lowering treatment costs, Cipla said in a regulatory filing.

Under the agreement, Qilu will be responsible for the development, regulatory registration, and supply of the product. At the same time, Cipla will leverage its commercial presence to market the asset in the US.

"This partnership reflects Cipla's confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio," said Achin Gupta, Managing Director and Global Chief Executive Officer, Cipla.

Ruto said the government would bring in two new companies to take over operations for Tata Chemicals.

“India sits at the heart of Heineken’s growth agenda, which is "expected to be the largest volume growth contributor" in Heineken's focus markets between 2026 and 2030, UBL said in its Investor Presentation.

The Indian subsidiary of Heineken NV also plans to expand EBITDA margins from the current high single digits to the low-to-mid teens over the medium term.

UBL said India is currently the "fastest-growing volume market" within the Heineken portfolio and offers significant headroom for long-term expansion, backed by favourable demographics, increasing disposable incomes and evolving consumer preferences.

The company, formerly known as Suven Pharmaceuticals, said the $13 million additional investment in NJ Bio will increase its common-equity ownership from 56% to 67.3%. The $5 million investment in Aruka Bio will provide Cohance a 65% controlling stake in the firm.

Both transactions will be funded through internal accruals, the company said in a release.

The re-organisation aims to integrate NJ Bio’s customer-facing services with Cohance's manufacturing capabilities to support end-to-end CRDMO development. NJ Bio will remain focused on contract research and manufacturing.

The expansion is expected to be completed by the end of FY29 and will entail an investment of around ₹3,000 crore, which will be funded through internal accruals and/or debt. The company currently has capacity utilisation of around 70%.

The company was declared the preferred bidder for a grant for leasing the Gundlupet rare earth element (REE) and Yttrium block, which extends over an area of 314.21 hectares in Chamrajnagar District, Karnataka, according to a regulatory filing dated September 3.

“Government of Karnataka has issued a Letter of Intent (LoI), pursuant to Rule 10(2) of the Mineral Auction Rules 2015, in favour of Hindustan Zinc Ltd, the preferred bidder for grant of a mining lease for the Gundlupet REE and Yttrium Block over an extent of 314.21 Hectares situated in Mallayanapur village, Gundlupet Taluka, Chamrajnagar District, Karnataka," the filing read.

According to a regulatory filing dated September 3, IEX said that it has recorded its highest-ever monthly electricity traded volume of 13,938 million units (MUs) in August 2026, marking a 20.2% year-on-year (YoY) increase.

India’s energy consumption touched 169.01 billion units (BUs) in August 2026, registering a YoY growth of 12.85%. This rise in power demand drove buy bids in the Day-Ahead Market up 61.7% year-on-year, resulting in an increase in prices.

Worth ₹1,152.49 crore, the project, titled “Transmission System for Integration of Power from RE Projects in Lakadia REZ in Gujarat-Phase II (7,500 MW),” will be developed on a Build, Own, Operate and Transfer (BOOT) basis.

Power Grid, in a regulatory filing, said that it has also received the Letter of Intent (LoI) for the project on September 3, 2026. The project will establish an interstate transmission system for the integration of power from renewable energy projects in Lakadia REZ in Gujarat.